Cialis Safety Signals and FDA Actions: What the Evidence Shows

How Tadalafil Works: The PDE5 Mechanism

Tadalafil inhibits phosphodiesterase type 5, an enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. During sexual stimulation, nitric oxide releases from cavernosal nerve terminals and endothelial cells, activating guanylate cyclase to produce cGMP. By blocking PDE5, tadalafil allows cGMP to accumulate, producing sustained smooth muscle relaxation and increased penile blood flow 1.

What separates tadalafil from sildenafil and vardenafil is pharmacokinetics. The drug reaches peak plasma concentration in approximately 2 hours and has an elimination half-life of 17.5 hours, compared to roughly 4 hours for sildenafil 2. This extended window is the reason Eli Lilly marketed it as "the weekend pill." The long half-life also enables once-daily dosing at 2.5 or 5 mg for both ED and BPH, a regimen the FDA approved in 2008 and 2011 respectively 3.

PDE5 is not exclusive to penile tissue. It appears in pulmonary vasculature, platelets, and systemic arterial smooth muscle. This broader distribution explains both the drug's therapeutic use in pulmonary arterial hypertension (marketed as Adcirca at 40 mg) and its hemodynamic side effects, particularly the 1 to 2 mmHg mean decrease in systolic blood pressure observed in clinical trials 3.

Regulatory Timeline: From Approval to Present

The FDA approved tadalafil for ED on November 21, 2003 under NDA 021368 3. The approval rested on five randomized, double-blind, placebo-controlled trials enrolling over 1,100 men. Brock et al. reported that tadalafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 7.9 points versus 1.4 for placebo (P<0.001) 1.

Key regulatory milestones after initial approval:

2005: The FDA requested a class-wide label revision for all PDE5 inhibitors to include warnings about NAION, a rare optic nerve condition that can cause sudden vision loss in one eye 4.

2007: A second class-wide update added sudden sensorineural hearing loss to the warnings and precautions section. The FDA noted 29 postmarketing reports across all PDE5 inhibitors, with a possible causal relationship that could not be ruled out 5.

2008: The FDA approved once-daily 2.5 mg and 5 mg dosing for ED, expanding the prescribing framework beyond on-demand use.

2011: Tadalafil 5 mg daily received FDA approval for BPH and the combination of BPH with ED, making it the only PDE5 inhibitor with this dual indication 3.

2018: Generic tadalafil entered the U.S. market following patent expiration, significantly increasing patient access.

No market withdrawal, REMS (Risk Evaluation and Mitigation Strategy), or black box warning has been issued for tadalafil as of May 2026.

The Nitrate Contraindication: Highest-Priority Safety Signal

Co-administration with organic nitrates is the single absolute contraindication for tadalafil. This is not a relative warning. Nitrates combined with any PDE5 inhibitor can produce severe, potentially fatal hypotension 3.

The mechanism is straightforward. Nitrates donate nitric oxide, which stimulates cGMP production. PDE5 inhibitors block cGMP breakdown. Together, the two drugs create an amplified vasodilatory effect that can drop blood pressure to dangerous levels. A pharmacodynamic study found that tadalafil 20 mg augmented the hypotensive effects of sublingual nitroglycerin 0.4 mg with a mean additional systolic BP decrease of approximately 7 mmHg beyond the nitrate effect alone 6.

Because tadalafil has a 17.5-hour half-life (compared to sildenafil's 4 hours), the nitrate-free interval is longer. The American Heart Association and ACC recommend waiting at least 48 hours after tadalafil before administering nitrates, versus 24 hours for shorter-acting PDE5 inhibitors 7. This distinction is clinically significant for emergency department physicians managing chest pain in men who have recently taken a PDE5 inhibitor. Getting the drug history right can prevent a lethal interaction.

Recreational "poppers" (amyl nitrite, butyl nitrite) carry the same risk. The FDA label explicitly includes these agents in the nitrate contraindication.

Cardiovascular Safety: What Pooled Data Show

Concerns about cardiac risk with PDE5 inhibitors date to the earliest postmarketing reports of myocardial infarction in men taking sildenafil. The critical question was whether the drug caused cardiac events or whether men with ED simply had high baseline cardiovascular risk.

For tadalafil specifically, Kloner et al. conducted a pooled analysis of 18,659 men across 68 clinical trials and found no increase in myocardial infarction rates compared with placebo 8. The incidence of MI in tadalafil-treated patients was 0.39 per 100 patient-years versus 0.49 in the placebo group. That pattern held across subgroups, including men with diabetes, hypertension, and those on antihypertensive medications.

The Princeton III Consensus Panel (2012) classified PDE5 inhibitors as safe for men at low cardiovascular risk and stated they can be used with most antihypertensive regimens 9.

One nuance deserves attention. Tadalafil produces modest systemic vasodilation. The label reports a mean reduction of 1.6 mmHg systolic and 0.8 mmHg diastolic across clinical trials. In men taking alpha-blockers such as tamsulosin for BPH, additive hypotension may occur. The FDA label recommends hemodynamic stability on alpha-blocker therapy before starting tadalafil, and starting with the lowest dose 3.

Dr. Robert Kloner, a cardiologist who led much of the PDE5 inhibitor cardiovascular research, has stated: "Tadalafil and other PDE5 inhibitors do not increase cardiac risk when used appropriately. The true danger is the nitrate interaction, not the drug itself" 8.

Vision Signals: NAION and Color Perception

In 2005 the FDA issued a class-wide alert for PDE5 inhibitors after postmarketing reports of NAION (non-arteritic anterior ischemic optic neuropathy), a condition involving sudden painless vision loss in one eye due to reduced blood flow to the optic nerve head 4.

NAION is rare even without PDE5 inhibitor exposure, affecting approximately 2 to 10 per 100,000 people annually in the general population over age 50. Establishing a clear causal link is difficult because risk factors for NAION (hypertension, diabetes, hyperlipidemia, smoking) overlap extensively with risk factors for ED 10.

A case-crossover study by McGwin et al. (2006) examined 38 NAION cases and found a statistically significant association with recent PDE5 inhibitor use (OR 2.15 to 95% CI 1.06 to 4.34) 11. Larger observational studies have been less consistent.

The current tadalafil label advises patients to stop taking the drug and seek immediate medical attention if sudden vision loss occurs in one or both eyes. Men with a prior history of NAION in one eye are considered at higher risk for recurrence and the label states this group should use PDE5 inhibitors with caution 3.

Color vision disturbances, particularly a blue tinge to vision (cyanopsia), are more commonly associated with sildenafil due to its cross-reactivity with PDE6 in retinal photoreceptors. Tadalafil has over 700-fold selectivity for PDE5 over PDE6, so visual color changes are rare at standard doses 2.

Hearing Loss: The 2007 Class-Wide Update

The FDA revised labeling for all three PDE5 inhibitors in October 2007 after identifying 29 reports of sudden sensorineural hearing loss associated with PDE5 inhibitor use 5. Some cases were accompanied by tinnitus and dizziness, and about one-third involved hearing loss that did not resolve.

Of those 29 cases, a subset involved tadalafil specifically. The FDA stated: "Although a causal relationship has not been established, physicians should advise patients to stop PDE5 inhibitor use and seek prompt medical attention in the event of sudden decrease or loss of hearing" 5.

A proposed mechanism involves PDE5 inhibition in the cochlear vasculature, where cGMP-mediated vasodilation could paradoxically impair blood flow in end-arteriole structures. This remains speculative. The absolute incidence appears very low based on the FAERS database, but the severity of the event (potentially permanent hearing loss) justified the label update 12.

Priapism and Prolonged Erection

Priapism, defined as an erection lasting 4 hours or longer, is a known class effect of PDE5 inhibitors. The tadalafil label reports this as a rare but serious adverse event requiring emergency intervention. Ischemic priapism left untreated beyond 4 to 6 hours can cause permanent corporal smooth muscle damage and irreversible erectile dysfunction 3.

Risk is elevated in patients with conditions predisposing to priapism: sickle cell disease, multiple myeloma, leukemia, and anatomical penile deformities such as Peyronie's disease. The prescribing information instructs clinicians to counsel these patients specifically about priapism risk before starting tadalafil.

In clinical trials enrolling over 15,000 men, the incidence of priapism with tadalafil was extremely rare. Postmarketing reports exist but remain infrequent relative to the millions of prescriptions dispensed annually. Generic tadalafil alone accounted for over 19 million U.S. dispensed prescriptions in 2023 according to ClinCalc estimates 13.

Drug Interactions Beyond Nitrates

Several drug classes interact with tadalafil through pharmacokinetic or pharmacodynamic pathways:

CYP3A4 inhibitors. Tadalafil is metabolized primarily by CYP3A4. Potent inhibitors such as ketoconazole and ritonavir increase tadalafil exposure significantly. Ketoconazole 400 mg daily increased tadalafil AUC by 312% in a pharmacokinetic study. The label recommends limiting the on-demand dose to 10 mg every 72 hours when co-administered with potent CYP3A4 inhibitors 3.

Alpha-blockers. Both tadalafil and alpha-blockers lower blood pressure through vasodilation. The FDA approved tadalafil 5 mg for BPH partly because it demonstrated efficacy comparable to tamsulosin in the MIST trial 14. Concomitant use is permitted but requires that the patient be stable on alpha-blocker therapy before adding tadalafil.

Antihypertensives. Tadalafil produces additive blood pressure lowering with amlodipine, enalapril, and metoprolol. In most patients this effect is clinically insignificant (1 to 3 mmHg additional decrease), but it can be meaningful in patients on multi-drug antihypertensive regimens or those prone to orthostatic hypotension 3.

Alcohol. Three or more standard alcoholic drinks taken with tadalafil can potentiate orthostatic hypotension. The label carries a specific precaution about excessive alcohol consumption.

Counterfeit and Unregulated Product Warnings

The FDA has issued over 60 public notifications since 2009 warning consumers about dietary supplements and online products found to contain undeclared tadalafil or sildenafil 15. These products, often marketed as "natural" or "herbal" male enhancement pills, bypass pharmaceutical regulation entirely.

The danger is twofold. Consumers may unknowingly ingest tadalafil while also taking nitrates or alpha-blockers. And the dosing in these products is uncontrolled, sometimes exceeding the maximum FDA-approved 20 mg on-demand dose. The FDA's BeSafeRx campaign specifically warns against purchasing PDE5 inhibitors from unverified online pharmacies.

Dr. Janet Woodcock, former FDA Commissioner, noted that "hidden drug ingredients in supplements remain one of the most persistent safety challenges the agency faces" in a 2021 FDA statement regarding tainted sexual enhancement products 15.

Current Monitoring and Open Questions

As of May 2026, no new safety signal has resulted in additional label changes since the 2011 BPH approval update. The FDA's FAERS (FDA Adverse Event Reporting System) database continues to collect postmarketing reports. Ongoing areas of pharmacovigilance interest include:

Long-term cardiovascular outcomes in men taking daily tadalafil 5 mg for BPH over periods exceeding 5 years. The original BPH trials ran for 12 to 26 weeks.

Potential melanoma association. A 2014 observational study (Li et al., JAMA Internal Medicine) reported a modest association between PDE5 inhibitor use and melanoma risk (adjusted HR 1.14 to 95% CI 1.01 to 1.29) 16. Subsequent studies have produced conflicting results. The FDA has not added a melanoma warning to the label, and a 2017 meta-analysis concluded the association was likely confounded by UV exposure and socioeconomic factors 17.

Cognitive effects at higher doses used for pulmonary hypertension (40 mg daily as Adcirca) are monitored separately under that indication's NDA.

Patients currently taking tadalafil should report any sudden vision changes, hearing loss, chest pain, or erections lasting longer than 4 hours to their prescriber or nearest emergency department immediately.